Green Thumb Industries Inc
CNSX:GTII
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (32.6), the stock would be worth CA$38.08 (238% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.6 | CA$11.26 |
0%
|
| 3-Year Average | 32.6 | CA$38.08 |
+238%
|
| 5-Year Average | 43.5 | CA$50.77 |
+351%
|
| Industry Average | 18.2 | CA$21.25 |
+89%
|
| Country Average | 21.9 | CA$25.53 |
+127%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| US |
G
|
Green Thumb Industries Inc
CNSX:GTII
|
2.6B CAD | 9.6 | 16.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
908.9B USD | 61.3 | 36 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.1B USD | 21 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 27.5 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.6B GBP | 36.2 | 27.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 9.4 | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.6B USD | 12.2 | 31.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -766.6 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 24.3 | 12.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
149.7B USD | 24.3 | 19.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.9B USD | 37.8 | 4 516.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.1 |
| Median | 21.9 |
| 70th Percentile | 36.5 |
| Max | 3 188 432.5 |
Other Multiples
Green Thumb Industries Inc
Glance View
Green Thumb Industries Inc., a notable player in the U.S. cannabis industry, operates like a well-tuned orchestra, harmonizing various elements of the cannabis business. The Chicago-based company is vertically integrated, meaning it controls each aspect of its product lifecycle—from cultivation to distribution. This structure enables Green Thumb to maintain consistency in its product quality while maximizing its operational efficiency. At the heart of its business model lies a diverse portfolio of well-regarded cannabis brands that cater to different consumer segments, from high-end connoisseurs to medicinal users seeking relief. These brands, including RYTHM, Dogwalkers, and Beboe, are strategically distributed across its extensive network of retail outlets, known as RISE dispensaries, as well as through wholesale channels. Like a savvy trader on a bustling market floor, Green Thumb’s profitability hinges on its ability to enhance scale while navigating the complex regulatory landscape. In each state where it operates, the company must tailor its approach to meet varying levels of regulation and market maturity. This agility provides Green Thumb with a competitive edge, allowing it to efficiently expand in both medical and adult-use markets while adhering to legal standards. The company generates revenue not only from its direct-to-consumer sales through dispensaries but also through wholesale transactions with other cannabis retailers. By maintaining robust relationships across these segments, Green Thumb underscores its position as a cornerstone of the cannabis industry's growth narrative.